drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00202 | DB09407 | 190 | 853 | [
"DDInter1716",
"DDInter1114"
] | Succinylcholine | Magnesium chloride | Succinylcholine is a depolarizing skeletal muscle relaxant consisting of two molecules of the endogenous neurotransmitter [acetylcholine] (ACh) linked by their acetyl groups. It has been widely used for over 50 years, most commonly in its chloride salt form, as a means of neuromuscular blockade during intubation and su... | Magnesium chloride salts are highly soluble in water and the hydrated form of magnesium chloride can be extracted from brine or sea water. | Moderate | 1 | [
[
[
190,
24,
853
]
],
[
[
190,
24,
964
],
[
964,
24,
853
]
],
[
[
190,
24,
964
],
[
964,
24,
544
],
[
544,
24,
853
]
],
[
[
190,
24,... | [
[
[
"Succinylcholine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium chloride"
]
],
[
[
"Succinylcholine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxycycli... | Succinylcholine may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Magnesium chloride
Succinylcholine may cause a moderate interaction that could exacerbate diseases when taken with D... |
DB00264 | DB00983 | 88 | 480 | [
"DDInter1200",
"DDInter776"
] | Metoprolol | Formoterol | Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succi... | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Moderate | 1 | [
[
[
88,
24,
480
]
],
[
[
88,
24,
1148
],
[
1148,
63,
480
]
],
[
[
88,
6,
1704
],
[
1704,
45,
480
]
],
[
[
88,
21,
28963
],
[
28963,
... | [
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
... | Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Metoprolol (Compound) binds ADRB1 (Gene) and ADRB1 (Gene) is bound by Formoterol (Compound)
Metoprolol (Comp... |
DB00238 | DB06209 | 188 | 256 | [
"DDInter1285",
"DDInter1508"
] | Nevirapine | Prasugrel | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Minor | 0 | [
[
[
188,
23,
256
]
],
[
[
188,
6,
8374
],
[
8374,
45,
256
]
],
[
[
188,
21,
28681
],
[
28681,
60,
256
]
],
[
[
188,
24,
593
],
[
593,
... | [
[
[
"Nevirapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prasugrel"
]
],
[
[
"Nevirapine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Nevirapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Prasugrel (Compound)
Nevirapine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Prasugrel (Compound)
Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Bupropi... |
DB00361 | DB00827 | 134 | 646 | [
"DDInter1939",
"DDInter383"
] | Vinorelbine | Cinoxacin | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections. | Minor | 0 | [
[
[
134,
23,
646
]
],
[
[
134,
21,
28722
],
[
28722,
60,
646
]
],
[
[
134,
24,
77
],
[
77,
62,
646
]
],
[
[
134,
24,
322
],
[
322,
2... | [
[
[
"Vinorelbine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cinoxacin"
]
],
[
[
"Vinorelbine",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {... | Vinorelbine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Cinoxacin (Compound)
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin may cause a minor interaction that can limit clinical effects when taken with Cinoxacin
Vino... |
DB06822 | DB12364 | 802 | 1,421 | [
"DDInter1812",
"DDInter200"
] | Tinzaparin | Betrixaban | Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for h... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Major | 2 | [
[
[
802,
25,
1421
]
],
[
[
802,
23,
297
],
[
297,
23,
1421
]
],
[
[
802,
23,
1631
],
[
1631,
62,
1421
]
],
[
[
802,
24,
992
],
[
992,
... | [
[
[
"Tinzaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Tinzaparin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"{u... | Tinzaparin may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Betrixaban
Tinzaparin may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a min... |
DB09073 | DB09083 | 951 | 880 | [
"DDInter1379",
"DDInter996"
] | Palbociclib | Ivabradine | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus r... | Moderate | 1 | [
[
[
951,
24,
880
]
],
[
[
951,
63,
1478
],
[
1478,
24,
880
]
],
[
[
951,
24,
159
],
[
159,
63,
880
]
],
[
[
951,
64,
1011
],
[
1011,
... | [
[
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivabradine"
]
],
[
[
"Palbociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
... | Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Palbociclib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Lar... |
DB00480 | DB09037 | 1,668 | 920 | [
"DDInter1035",
"DDInter1413"
] | Lenalidomide | Pembrolizumab | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenali... | Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues and ... | Major | 2 | [
[
[
1668,
25,
920
]
],
[
[
1668,
1,
770
],
[
770,
25,
920
]
],
[
[
1668,
5,
11555
],
[
11555,
44,
891
],
[
891,
24,
920
]
],
[
[
1668,
... | [
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pembrolizumab"
]
],
[
[
"Lenalidomide",
"{u} (Compound) resembles {v} (Compound)",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life ... | Lenalidomide (Compound) resembles Thalidomide (Compound) and Thalidomide may lead to a major life threatening interaction when taken with Pembrolizumab
Lenalidomide (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Prednisolone (Compound) and Prednisolone may cause a moderate... |
DB01124 | DB01125 | 1,411 | 279 | [
"DDInter1828",
"DDInter98"
] | Tolbutamide | Anisindione | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagu... | Moderate | 1 | [
[
[
1411,
24,
279
]
],
[
[
1411,
24,
712
],
[
712,
62,
279
]
],
[
[
1411,
24,
913
],
[
913,
63,
279
]
],
[
[
1411,
63,
175
],
[
175,
... | [
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olsalazine"
],
[... | Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine may cause a minor interaction that can limit clinical effects when taken with Anisindione
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apal... |
DB00862 | DB08912 | 1,005 | 1,040 | [
"DDInter1918",
"DDInter462"
] | Vardenafil | Dabrafenib | Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction.[L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, ... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
1005,
24,
1040
]
],
[
[
1005,
6,
8374
],
[
8374,
45,
1040
]
],
[
[
1005,
21,
28900
],
[
28900,
60,
1040
]
],
[
[
1005,
25,
478
],
[
47... | [
[
[
"Vardenafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Vardenafil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Vardenafil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dabrafenib (Compound)
Vardenafil (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (Compound)
Vardenafil may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib ... |
DB00631 | DB01015 | 372 | 1,247 | [
"DDInter405",
"DDInter1724"
] | Clofarabine | Sulfamethoxazole | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Sulfamethoxazole is a bacteriostatic sulfonamide antibiotic that interferes with folic acid synthesis in susceptible bacteria. It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps i... | Moderate | 1 | [
[
[
372,
24,
1247
]
],
[
[
372,
63,
1029
],
[
1029,
1,
1247
]
],
[
[
372,
24,
698
],
[
698,
1,
1247
]
],
[
[
372,
7,
9900
],
[
9900,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfamethoxazole"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfisoxazole"
... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Sulfisoxazole and Sulfisoxazole (Compound) resembles Sulfamethoxazole (Compound)
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Sulfadoxine and Sulfadoxine (Compound) resembles Sulfam... |
DB00279 | DB00373 | 1,152 | 461 | [
"DDInter1074",
"DDInter1809"
] | Liothyronine | Timolol | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmace... | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective ag... | Minor | 0 | [
[
[
1152,
23,
461
]
],
[
[
1152,
23,
729
],
[
729,
40,
461
]
],
[
[
1152,
6,
4973
],
[
4973,
45,
461
]
],
[
[
1152,
21,
29434
],
[
29434,
... | [
[
[
"Liothyronine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Timolol"
]
],
[
[
"Liothyronine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Penbutolol"
],
[
... | Liothyronine may cause a minor interaction that can limit clinical effects when taken with Penbutolol and Penbutolol (Compound) resembles Timolol (Compound)
Liothyronine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Timolol (Compound)
Liothyronine (Compound) causes Angina pectoris (Side Effect) and Angina ... |
DB04843 | DB06702 | 1,511 | 573 | [
"DDInter1149",
"DDInter731"
] | Mepenzolate | Fesoterodine | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome. | Moderate | 1 | [
[
[
1511,
24,
573
]
],
[
[
1511,
63,
211
],
[
211,
1,
573
]
],
[
[
1511,
6,
2720
],
[
2720,
45,
573
]
],
[
[
1511,
21,
28681
],
[
28681,
... | [
[
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fesoterodine"
]
],
[
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],
... | Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine (Compound) resembles Fesoterodine (Compound)
Mepenzolate (Compound) binds CHRM3 (Gene) and CHRM3 (Gene) is bound by Fesoterodine (Compound)
Mepenzolate (Compound) causes Hypersensitivity (Side Effect)... |
DB00328 | DB00348 | 831 | 254 | [
"DDInter921",
"DDInter1300"
] | Indomethacin | Nitisinone | Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlor... | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | Moderate | 1 | [
[
[
831,
24,
254
]
],
[
[
831,
21,
29097
],
[
29097,
60,
254
]
],
[
[
831,
24,
1144
],
[
1144,
63,
254
]
],
[
[
831,
63,
245
],
[
245,
... | [
[
[
"Indomethacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitisinone"
]
],
[
[
"Indomethacin",
"{u} (Compound) causes {v} (Side Effect)",
"Eye pain"
],
[
"Eye pain",
"{u} (Side Effect) is ca... | Indomethacin (Compound) causes Eye pain (Side Effect) and Eye pain (Side Effect) is caused by Nitisinone (Compound)
Indomethacin may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Nit... |
DB00488 | DB06168 | 196 | 1,531 | [
"DDInter57",
"DDInter281"
] | Altretamine | Canakinumab | An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects. | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Moderate | 1 | [
[
[
196,
24,
1531
]
],
[
[
196,
63,
1461
],
[
1461,
23,
1531
]
],
[
[
196,
24,
1270
],
[
1270,
63,
1531
]
],
[
[
196,
24,
697
],
[
697,
... | [
[
[
"Altretamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Altretamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Altretamine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Canakinumab
Altretamine may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified pr... |
DB01364 | DB14754 | 22 | 1,663 | [
"DDInter650",
"DDInter1697"
] | Ephedrine | Solriamfetol | Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. Ephedrine acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepine... | Solriamfetol marketed under the brand name Sunosi by Jazz Pharmaceuticals in the United States is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated in treating daytime sleepiness associated with narcolepsy or obstructive sleep apnea[FDA Label]. Solriamfetol was given FDA approval in 2019[FDA Label]. | Moderate | 1 | [
[
[
22,
24,
1663
]
],
[
[
22,
63,
1674
],
[
1674,
24,
1663
]
],
[
[
22,
24,
659
],
[
659,
24,
1663
]
],
[
[
22,
40,
1445
],
[
1445,
... | [
[
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solriamfetol"
]
],
[
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
],
[... | Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Solriamfetol
Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and ... |
DB01242 | DB12267 | 1,237 | 1,476 | [
"DDInter410",
"DDInter233"
] | Clomipramine | Brigatinib | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
1237,
24,
1476
]
],
[
[
1237,
63,
918
],
[
918,
24,
1476
]
],
[
[
1237,
64,
1133
],
[
1133,
24,
1476
]
],
[
[
1237,
24,
1421
],
[
1421... | [
[
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
... | Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Clomipramine may lead to a major life threatening interaction when taken with Granisetron and Granisetron ... |
DB01211 | DB11730 | 609 | 351 | [
"DDInter393",
"DDInter1588"
] | Clarithromycin | Ribociclib | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
609,
25,
351
]
],
[
[
609,
23,
271
],
[
271,
23,
351
]
],
[
[
609,
24,
466
],
[
466,
62,
351
]
],
[
[
609,
62,
1247
],
[
1247,
2... | [
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
[
"Mira... | Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and ... |
DB00012 | DB00480 | 1,535 | 1,668 | [
"DDInter479",
"DDInter1035"
] | Darbepoetin alfa | Lenalidomide | Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenali... | Major | 2 | [
[
[
1535,
25,
1668
]
],
[
[
1535,
25,
770
],
[
770,
40,
1668
]
],
[
[
1535,
24,
1514
],
[
1514,
64,
1668
]
],
[
[
1535,
25,
770
],
[
770,
... | [
[
[
"Darbepoetin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenalidomide"
]
],
[
[
"Darbepoetin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomid... | Darbepoetin alfa may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide (Compound) resembles Lenalidomide (Compound)
Darbepoetin alfa may cause a moderate interaction that could exacerbate diseases when taken with Human C1-esterase inhibitor and Human C1-esterase inhibitor may lead... |
DB00549 | DB09121 | 522 | 1,328 | [
"DDInter1955",
"DDInter140"
] | Zafirlukast | Aurothioglucose | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Aurothioglucose, also known as gold thioglucose, was formerly used to treat rheumatoid arthritis. Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression in patients with rheumatoid arthritis . The use of gold compounds has decreased si... | Moderate | 1 | [
[
[
522,
24,
1328
]
],
[
[
522,
63,
367
],
[
367,
24,
1328
]
],
[
[
522,
24,
310
],
[
310,
24,
1328
]
],
[
[
522,
24,
148
],
[
148,
... | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aurothioglucose"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon alfacon-1... | Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1 and Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken... |
DB00773 | DB11627 | 896 | 1,367 | [
"DDInter702",
"DDInter860"
] | Etoposide | Hepatitis B Vaccine (Recombinant) | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Moderate | 1 | [
[
[
896,
24,
1367
]
],
[
[
896,
63,
1648
],
[
1648,
24,
1367
]
],
[
[
896,
64,
1064
],
[
1064,
24,
1367
]
],
[
[
896,
24,
1480
],
[
1480,
... | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesl... | Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Etoposide may lead to a major life threatening interaction when taken with Cladribine an... |
DB00176 | DB05578 | 529 | 330 | [
"DDInter770",
"DDInter1566"
] | Fluvoxamine | Ramucirumab | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stim... | Moderate | 1 | [
[
[
529,
24,
330
]
],
[
[
529,
25,
222
],
[
222,
24,
330
]
],
[
[
529,
24,
1317
],
[
1317,
25,
330
]
],
[
[
529,
24,
397
],
[
397,
6... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramucirumab"
]
],
[
[
"Fluvoxamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutr... | Fluvoxamine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Dipyridamole and Dipyridamole m... |
DB00065 | DB00794 | 581 | 759 | [
"DDInter923",
"DDInter1521"
] | Infliximab | Primidone | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Moderate | 1 | [
[
[
581,
24,
759
]
],
[
[
581,
24,
697
],
[
697,
40,
759
]
],
[
[
581,
24,
362
],
[
362,
1,
759
]
],
[
[
581,
25,
1101
],
[
1101,
23... | [
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
],
[
... | Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital (Compound) resembles Primidone (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Primidone (Compound... |
DB14443 | DB14762 | 987 | 994 | [
"DDInter1931",
"DDInter1602"
] | Vibrio cholerae CVD 103-HgR strain live antigen | Risankizumab | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, ... | Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease... | Moderate | 1 | [
[
[
987,
24,
994
]
],
[
[
987,
63,
4
],
[
4,
24,
994
]
],
[
[
987,
24,
676
],
[
676,
64,
994
]
],
[
[
987,
63,
1510
],
[
1510,
25,
... | [
[
[
"Vibrio cholerae CVD 103-HgR strain live antigen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risankizumab"
]
],
[
[
"Vibrio cholerae CVD 103-HgR strain live antigen",
"{u} may cause a moderate interaction that could ... | Vibrio cholerae CVD 103-HgR strain live antigen may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Risankizumab
Vibrio cholerae CVD 103-HgR strain live ant... |
DB00195 | DB09080 | 726 | 144 | [
"DDInter198",
"DDInter1331"
] | Betaxolol (ophthalmic) | Olodaterol | Betaxolol is a propanolamine that is 3-aminopropane-1,2-diol in which the hydrogen of the primary hydoxy is substituted by a 4-[2-(cyclopropylmethoxy)ethyl]phenyl group and one of the hydrogens attached to the amino group is substituted by isopropyl. It is a selective beta1-receptor blocker and is used in the treatment... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
726,
24,
144
]
],
[
[
726,
24,
455
],
[
455,
24,
144
]
],
[
[
726,
25,
1031
],
[
1031,
24,
144
]
],
[
[
726,
1,
1121
],
[
1121,
... | [
[
[
"Betaxolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Betaxolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
... | Betaxolol may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Betaxolol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Betaxolol ma... |
DB00991 | DB11921 | 97 | 1,019 | [
"DDInter1358",
"DDInter492"
] | Oxaprozin | Deflazacort | Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
97,
24,
1019
]
],
[
[
97,
24,
959
],
[
959,
24,
1019
]
],
[
[
97,
64,
629
],
[
629,
24,
1019
]
],
[
[
97,
75,
126
],
[
126,
24,
... | [
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Oxaprozin may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a mod... |
DB01238 | DB11837 | 673 | 1,297 | [
"DDInter118",
"DDInter1351"
] | Aripiprazole | Osilodrostat | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
673,
24,
1297
]
],
[
[
673,
62,
112
],
[
112,
23,
1297
]
],
[
[
673,
63,
222
],
[
222,
23,
1297
]
],
[
[
673,
24,
1320
],
[
1320,
... | [
[
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Aripiprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Aripiprazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine a... |
DB09038 | DB11652 | 1,450 | 1,155 | [
"DDInter636",
"DDInter1891"
] | Empagliflozin | Tucatinib | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Moderate | 1 | [
[
[
1450,
24,
1155
]
],
[
[
1450,
63,
222
],
[
222,
23,
1155
]
],
[
[
1450,
24,
659
],
[
659,
24,
1155
]
],
[
[
1450,
63,
609
],
[
609,
... | [
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
... | Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and V... |
DB01072 | DB08912 | 915 | 1,040 | [
"DDInter129",
"DDInter462"
] | Atazanavir | Dabrafenib | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses p... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
915,
24,
1040
]
],
[
[
915,
6,
13478
],
[
13478,
45,
1040
]
],
[
[
915,
21,
28900
],
[
28900,
60,
1040
]
],
[
[
915,
63,
168
],
[
168,... | [
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Atazanavir",
"{u} (Compound) binds {v} (Gene)",
"SLCO1B3"
],
[
"SLCO1B3",
"{u} (Gene) is bound by {v} (Compound)... | Atazanavir (Compound) binds SLCO1B3 (Gene) and SLCO1B3 (Gene) is bound by Dabrafenib (Compound)
Atazanavir (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (Compound)
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Bortezo... |
DB00813 | DB09074 | 704 | 1,362 | [
"DDInter722",
"DDInter1327"
] | Fentanyl | Olaparib | Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
704,
24,
1362
]
],
[
[
704,
40,
576
],
[
576,
24,
1362
]
],
[
[
704,
24,
1683
],
[
1683,
24,
1362
]
],
[
[
704,
63,
353
],
[
353,
... | [
[
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Fentanyl",
"{u} (Compound) resembles {v} (Compound)",
"Methadone"
],
[
"Methadone",
"{u} may cause a moderate intera... | Fentanyl (Compound) resembles Methadone (Compound) and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exace... |
DB00348 | DB00678 | 254 | 240 | [
"DDInter1300",
"DDInter1095"
] | Nitisinone | Losartan | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough simila... | Moderate | 1 | [
[
[
254,
24,
240
]
],
[
[
254,
21,
29404
],
[
29404,
60,
240
]
],
[
[
254,
24,
129
],
[
129,
63,
240
]
],
[
[
254,
63,
600
],
[
600,
... | [
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Losartan"
]
],
[
[
"Nitisinone",
"{u} (Compound) causes {v} (Side Effect)",
"Cataract"
],
[
"Cataract",
"{u} (Side Effect) is caused b... | Nitisinone (Compound) causes Cataract (Side Effect) and Cataract (Side Effect) is caused by Losartan (Compound)
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Losarta... |
DB01059 | DB01124 | 956 | 1,411 | [
"DDInter1313",
"DDInter1828"
] | Norfloxacin | Tolbutamide | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Major | 2 | [
[
[
956,
25,
1411
]
],
[
[
956,
25,
959
],
[
959,
40,
1411
]
],
[
[
956,
64,
245
],
[
245,
40,
1411
]
],
[
[
956,
6,
10612
],
[
10612,
... | [
[
[
"Norfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tolbutamide"
]
],
[
[
"Norfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} ... | Norfloxacin may lead to a major life threatening interaction when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Norfloxacin may lead to a major life threatening interaction when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compound)
Norfloxacin (Compound) bin... |
DB00762 | DB12500 | 613 | 283 | [
"DDInter973",
"DDInter714"
] | Irinotecan | Fedratinib | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
613,
24,
283
]
],
[
[
613,
24,
466
],
[
466,
62,
283
]
],
[
[
613,
24,
351
],
[
351,
23,
283
]
],
[
[
613,
63,
122
],
[
122,
23,... | [
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
... | Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribo... |
DB00196 | DB00976 | 600 | 1,056 | [
"DDInter743",
"DDInter1758"
] | Fluconazole | Telithromycin | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with ... | Moderate | 1 | [
[
[
600,
24,
1056
]
],
[
[
600,
24,
1570
],
[
1570,
40,
1056
]
],
[
[
600,
6,
7524
],
[
7524,
45,
1056
]
],
[
[
600,
21,
28681
],
[
28681,... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telithromycin"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azithromycin"
],
... | Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin and Azithromycin (Compound) resembles Telithromycin (Compound)
Fluconazole (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Telithromycin (Compound)
Fluconazole (Compound) causes Hypersensitivity (Side E... |
DB00414 | DB04865 | 590 | 4 | [
"DDInter16",
"DDInter1335"
] | Acetohexamide | Omacetaxine mepesuccinate | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Moderate | 1 | [
[
[
590,
24,
4
]
],
[
[
590,
24,
485
],
[
485,
24,
4
]
],
[
[
590,
24,
1616
],
[
1616,
63,
4
]
],
[
[
590,
63,
1645
],
[
1645,
24,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentam... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00881 | DB09104 | 954 | 286 | [
"DDInter1554",
"DDInter1118"
] | Quinapril | Magnesium hydroxide | Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta b... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Minor | 0 | [
[
[
954,
23,
286
]
],
[
[
954,
24,
820
],
[
820,
23,
286
]
],
[
[
954,
40,
610
],
[
610,
23,
286
]
],
[
[
954,
63,
999
],
[
999,
23,... | [
[
[
"Quinapril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
... | Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Quinapril (Compound) resembles Enalapril (Compound) and Enalapril may cause a minor interaction that can... |
DB00544 | DB10343 | 970 | 962 | [
"DDInter757",
"DDInter160"
] | Fluorouracil | Bacillus calmette-guerin substrain tice live antigen | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of *Mycobacterium bovis* for percutaneous use. It is administered to prevent the development of tuberculosis. | Major | 2 | [
[
[
970,
25,
962
]
],
[
[
970,
64,
1057
],
[
1057,
25,
962
]
],
[
[
970,
24,
270
],
[
270,
64,
962
]
],
[
[
970,
24,
663
],
[
663,
2... | [
[
[
"Fluorouracil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Fluorouracil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"... | Fluorouracil may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Ocrel... |
DB01233 | DB09039 | 1,311 | 1,670 | [
"DDInter1197",
"DDInter629"
] | Metoclopramide | Eliglustat | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Moderate | 1 | [
[
[
1311,
24,
1670
]
],
[
[
1311,
63,
211
],
[
211,
23,
1670
]
],
[
[
1311,
63,
121
],
[
121,
24,
1670
]
],
[
[
1311,
64,
1664
],
[
1664,
... | [
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],... | Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine ... |
DB00620 | DB09280 | 175 | 1,604 | [
"DDInter1855",
"DDInter1101"
] | Triamcinolone | Lumacaftor | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Moderate | 1 | [
[
[
175,
24,
1604
]
],
[
[
175,
24,
1171
],
[
1171,
24,
1604
]
],
[
[
175,
25,
593
],
[
593,
24,
1604
]
],
[
[
175,
40,
1573
],
[
1573,
... | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meloxicam"
],
... | Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Meloxicam and Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Triamcinolone may lead to a major life threatening interaction when taken with Bupropion and Bupropion may caus... |
DB01148 | DB09272 | 1,128 | 412 | [
"DDInter738",
"DDInter632"
] | Flavoxate | Eluxadoline | A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. [PubChem] | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system ... | Moderate | 1 | [
[
[
1128,
24,
412
]
],
[
[
1128,
63,
1594
],
[
1594,
24,
412
]
],
[
[
1128,
24,
830
],
[
830,
24,
412
]
],
[
[
1128,
24,
407
],
[
407,
... | [
[
[
"Flavoxate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Flavoxate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Flavoxate may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Flavoxate may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Pheni... |
DB00333 | DB06616 | 576 | 594 | [
"DDInter1166",
"DDInter224"
] | Methadone | Bosutinib | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Major | 2 | [
[
[
576,
25,
594
]
],
[
[
576,
6,
8374
],
[
8374,
45,
594
]
],
[
[
576,
21,
28709
],
[
28709,
60,
594
]
],
[
[
576,
23,
112
],
[
112,
... | [
[
[
"Methadone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
]
],
[
[
"Methadone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Bosutinib"... | Methadone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Methadone (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Bosutinib (Compound)
Methadone may cause a minor interaction that can limit clinical effects when taken with Metronid... |
DB06043 | DB08904 | 1,644 | 375 | [
"DDInter1328",
"DDInter342"
] | Olaratumab | Certolizumab pegol | Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody with antitumor activity that selectively binds the external domain of human platelet-derived growth factor receptor (PDGFR)-α with high affinity and blocks ligand binding. It is composed of two heavy chain molecule fragments and 2 light chain fragments. Stu... | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Major | 2 | [
[
[
1644,
25,
375
]
],
[
[
1644,
24,
200
],
[
200,
63,
375
]
],
[
[
1644,
63,
66
],
[
66,
24,
375
]
],
[
[
1644,
24,
1430
],
[
1430,
... | [
[
[
"Olaratumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Olaratumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
],
[
... | Olaratumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Olaratumab may cause a moderate interaction that could exacerbate diseases when taken with E... |
DB00342 | DB01159 | 1,181 | 419 | [
"DDInter1770",
"DDInter854"
] | Terfenadine | Halothane | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required... | Moderate | 1 | [
[
[
1181,
24,
419
]
],
[
[
1181,
23,
112
],
[
112,
23,
419
]
],
[
[
1181,
24,
629
],
[
629,
24,
419
]
],
[
[
1181,
24,
774
],
[
774,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Halothane"
]
],
[
[
"Terfenadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Terfenadine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Halothane
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Siro... |
DB00346 | DB01088 | 472 | 714 | [
"DDInter44",
"DDInter908"
] | Alfuzosin | Iloprost | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Moderate | 1 | [
[
[
472,
24,
714
]
],
[
[
472,
1,
1205
],
[
1205,
24,
714
]
],
[
[
472,
24,
1445
],
[
1445,
24,
714
]
],
[
[
472,
24,
1450
],
[
1450,
... | [
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
]
],
[
[
"Alfuzosin",
"{u} (Compound) resembles {v} (Compound)",
"Prazosin"
],
[
"Prazosin",
"{u} may cause a moderate intera... | Alfuzosin (Compound) resembles Prazosin (Compound) and Prazosin may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may cause a moderate interaction that cou... |
DB00813 | DB11834 | 704 | 1,303 | [
"DDInter722",
"DDInter849"
] | Fentanyl | Guselkumab | Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and... | Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstra... | Moderate | 1 | [
[
[
704,
24,
1303
]
],
[
[
704,
63,
58
],
[
58,
24,
1303
]
],
[
[
704,
1,
371
],
[
371,
24,
1303
]
],
[
[
704,
40,
1454
],
[
1454,
2... | [
[
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guselkumab"
]
],
[
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"... | Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab
Fentanyl (Compound) resembles Propafenone (Compound) and Propafenone may cause a moderate interaction that could exa... |
DB06663 | DB15822 | 1,154 | 69 | [
"DDInter1398",
"DDInter1504"
] | Pasireotide | Pralsetinib | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Pralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small... | Moderate | 1 | [
[
[
1154,
24,
69
]
],
[
[
1154,
1,
966
],
[
966,
24,
69
]
],
[
[
1154,
64,
1213
],
[
1213,
24,
69
]
],
[
[
1154,
25,
985
],
[
985,
2... | [
[
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pralsetinib"
]
],
[
[
"Pasireotide",
"{u} (Compound) resembles {v} (Compound)",
"Octreotide"
],
[
"Octreotide",
"{u} may cause a mode... | Pasireotide (Compound) resembles Octreotide (Compound) and Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Pralsetinib
Pasireotide may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate di... |
DB00798 | DB15066 | 1,132 | 445 | [
"DDInter815",
"DDInter821"
] | Gentamicin | Givosiran | Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from _Micromonospora purpurea_ in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability.[A234339,A234354] Gentamicin is effective against both gram-positive and gram-negat... | Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a... | Moderate | 1 | [
[
[
1132,
24,
445
]
],
[
[
1132,
63,
1555
],
[
1555,
24,
445
]
],
[
[
1132,
24,
1272
],
[
1272,
24,
445
]
],
[
[
1132,
35,
416
],
[
416,
... | [
[
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
... | Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Flucytosine and Fluc... |
DB00575 | DB01067 | 1,020 | 959 | [
"DDInter412",
"DDInter826"
] | Clonidine | Glipizide | Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors. This activity is useful for the treatment of hypertension, severe pain, and ADHD.[L7237,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974. | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
1020,
24,
959
]
],
[
[
1020,
63,
245
],
[
245,
40,
959
]
],
[
[
1020,
24,
1411
],
[
1411,
1,
959
]
],
[
[
1020,
6,
8374
],
[
8374,
... | [
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
... | Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compound)
... |
DB00196 | DB01244 | 600 | 762 | [
"DDInter743",
"DDInter192"
] | Fluconazole | Bepridil | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United St... | Major | 2 | [
[
[
600,
25,
762
]
],
[
[
600,
25,
704
],
[
704,
1,
762
]
],
[
[
600,
24,
675
],
[
675,
40,
762
]
],
[
[
600,
6,
4973
],
[
4973,
45,... | [
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bepridil"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fentanyl"
],
[
"Fentanyl",
"{u} (Comp... | Fluconazole may lead to a major life threatening interaction when taken with Fentanyl and Fentanyl (Compound) resembles Bepridil (Compound)
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene (Compound) resembles Bepridil (Compound)
Fluco... |
DB00059 | DB00108 | 1,560 | 1,066 | [
"DDInter1404",
"DDInter1268"
] | Pegaspargase | Natalizumab | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Major | 2 | [
[
[
1560,
25,
1066
]
],
[
[
1560,
24,
949
],
[
949,
63,
1066
]
],
[
[
1560,
25,
375
],
[
375,
64,
1066
]
],
[
[
1560,
24,
372
],
[
372,
... | [
[
[
"Pegaspargase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (fo... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Natalizumab
Pegasparg... |
DB00305 | DB00675 | 377 | 888 | [
"DDInter1232",
"DDInter1744"
] | Mitomycin | Tamoxifen | Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of th... | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Moderate | 1 | [
[
[
377,
24,
888
]
],
[
[
377,
6,
4973
],
[
4973,
45,
888
]
],
[
[
377,
7,
4634
],
[
4634,
46,
888
]
],
[
[
377,
18,
17537
],
[
17537,
... | [
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
]
],
[
[
"Mitomycin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Mitomycin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Tamoxifen (Compound)
Mitomycin (Compound) upregulates FOXO4 (Gene) and FOXO4 (Gene) is upregulated by Tamoxifen (Compound)
Mitomycin (Compound) downregulates USP6NL (Gene) and USP6NL (Gene) is upregulated by Tamoxifen (Compound)
Mitomycin (Compound) d... |
DB01501 | DB08883 | 1,118 | 1,597 | [
"DDInter549",
"DDInter1428"
] | Difenoxin | Perampanel | Difenoxin is a 4-phenylpiperidine which is closely related to the opioid analgesic meperidine. Difenoxin alone is a USA Schedule I controlled drug, as it may be habit forming. However, it is listed as a Schedule IV controlled drug if combined with atropine, which is added to decrease deliberate misuse. Motofen(R) is a ... | Perampanel is a noncompetitive AMPA glutamate receptor antagonist. It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures. The FDA label includes an important black-boxed warning ... | Moderate | 1 | [
[
[
1118,
24,
1597
]
],
[
[
1118,
24,
649
],
[
649,
24,
1597
]
],
[
[
1118,
1,
1688
],
[
1688,
24,
1597
]
],
[
[
1118,
63,
506
],
[
506,
... | [
[
[
"Difenoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perampanel"
]
],
[
[
"Difenoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
... | Difenoxin may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Perampanel
Difenoxin (Compound) resembles Diphenoxylate (Compound) and Diphenoxylate may cause a moderate interaction that c... |
DB00570 | DB08860 | 147 | 788 | [
"DDInter1936",
"DDInter1479"
] | Vinblastine | Pitavastatin | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Pitavastatin, also known as the brand name product Livalo, is a lipid-lowering drug belonging to the statin class of medications. By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease. More sp... | Moderate | 1 | [
[
[
147,
24,
788
]
],
[
[
147,
24,
671
],
[
671,
1,
788
]
],
[
[
147,
24,
700
],
[
700,
40,
788
]
],
[
[
147,
6,
4973
],
[
4973,
45,... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin (Compound) resembles Pitavastatin (Compound)
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Atorvastatin and Atorvastatin (Compound) resembles Pitavastatin... |
DB01284 | DB09268 | 1,042 | 1,662 | [
"DDInter1782",
"DDInter1464"
] | Tetracosactide | Picosulfuric acid | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
1042,
24,
1662
]
],
[
[
1042,
63,
997
],
[
997,
24,
1662
]
],
[
[
1042,
24,
877
],
[
877,
63,
1662
]
],
[
[
1042,
24,
1372
],
[
1372,
... | [
[
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methazolamid... | Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Methazolamide and Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00396 | DB01254 | 989 | 1,213 | [
"DDInter1529",
"DDInter484"
] | Progesterone | Dasatinib | Progesterone is a hormone that occurs naturally in females, and is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss. Progesterone is used in var... | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Moderate | 1 | [
[
[
989,
24,
1213
]
],
[
[
989,
6,
10509
],
[
10509,
45,
1213
]
],
[
[
989,
7,
7669
],
[
7669,
46,
1213
]
],
[
[
989,
18,
8914
],
[
8914,
... | [
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Progesterone",
"{u} (Compound) binds {v} (Gene)",
"CYP1B1"
],
[
"CYP1B1",
"{u} (Gene) is bound by {v} (Compound... | Progesterone (Compound) binds CYP1B1 (Gene) and CYP1B1 (Gene) is bound by Dasatinib (Compound)
Progesterone (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Dasatinib (Compound)
Progesterone (Compound) downregulates NUP85 (Gene) and NUP85 (Gene) is downregulated by Dasatinib (Compound)
Progesteron... |
DB00795 | DB12015 | 50 | 1,033 | [
"DDInter1725",
"DDInter53"
] | Sulfasalazine | Alpelisib | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down i... | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
50,
24,
1033
]
],
[
[
50,
24,
1254
],
[
1254,
24,
1033
]
],
[
[
50,
63,
1144
],
[
1144,
24,
1033
]
],
[
[
50,
25,
1510
],
[
1510,
... | [
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
... | Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Na... |
DB00425 | DB08912 | 558 | 1,040 | [
"DDInter1970",
"DDInter462"
] | Zolpidem | Dabrafenib | Zolpidem, also known as _Ambien_, is a hypnotic drug that was initially approved by the FDA in 1992 [FDA label]. Zolpidem improves sleep in patients with insomnia. It is aimed for use in patients with difficulties initiating sleep. This drug decreases the time to fall asleep (sleep latency), increases the duration of s... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
558,
24,
1040
]
],
[
[
558,
6,
8374
],
[
8374,
45,
1040
]
],
[
[
558,
21,
28900
],
[
28900,
60,
1040
]
],
[
[
558,
63,
1101
],
[
1101,... | [
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Zolpidem",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Zolpidem (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dabrafenib (Compound)
Zolpidem (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (Compound)
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and ... |
DB00544 | DB00619 | 970 | 1,419 | [
"DDInter757",
"DDInter909"
] | Fluorouracil | Imatinib | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Moderate | 1 | [
[
[
970,
24,
1419
]
],
[
[
970,
6,
6017
],
[
6017,
45,
1419
]
],
[
[
970,
21,
28762
],
[
28762,
60,
1419
]
],
[
[
970,
24,
1686
],
[
1686,... | [
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Fluorouracil",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)... | Fluorouracil (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Imatinib (Compound)
Fluorouracil (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Imatinib (Compound)
Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Temozolomide and Te... |
DB00759 | DB14509 | 1,620 | 1,399 | [
"DDInter1783",
"DDInter1081"
] | Tetracycline | Lithium carbonate | Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some e... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Minor | 0 | [
[
[
1620,
23,
1399
]
],
[
[
1620,
1,
964
],
[
964,
23,
1399
]
],
[
[
1620,
62,
1010
],
[
1010,
24,
1399
]
],
[
[
1620,
63,
1031
],
[
1031,... | [
[
[
"Tetracycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Tetracycline",
"{u} (Compound) resembles {v} (Compound)",
"Doxycycline"
],
[
"Doxycycline",
"{u} may caus... | Tetracycline (Compound) resembles Doxycycline (Compound) and Doxycycline may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Tetracycline may cause a minor interaction that can limit clinical effects when taken with Mefloquine and Mefloquine may cause a moderate interaction t... |
DB00374 | DB00598 | 1,061 | 1,523 | [
"DDInter1852",
"DDInter1013"
] | Treprostinil | Labetalol | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Moderate | 1 | [
[
[
1061,
24,
1523
]
],
[
[
1061,
24,
935
],
[
935,
1,
1523
]
],
[
[
1061,
24,
1274
],
[
1274,
63,
1523
]
],
[
[
1061,
18,
3576
],
[
3576,... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoprofen"
],
[... | Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen (Compound) resembles Labetalol (Compound)
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction tha... |
DB00321 | DB00771 | 21 | 262 | [
"DDInter78",
"DDInter397"
] | Amitriptyline | Clidinium | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | Moderate | 1 | [
[
[
21,
24,
262
]
],
[
[
21,
24,
1511
],
[
1511,
63,
262
]
],
[
[
21,
6,
2720
],
[
2720,
45,
262
]
],
[
[
21,
24,
19
],
[
19,
24,
... | [
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clidinium"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
... | Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Clidinium
Amitriptyline (Compound) binds CHRM3 (Gene) and CHRM3 (Gene) is bound by Clidinium (Compound)
Amitriptyline ... |
DB00631 | DB05528 | 372 | 1,070 | [
"DDInter405",
"DDInter1228"
] | Clofarabine | Mipomersen | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. M... | Major | 2 | [
[
[
372,
25,
1070
]
],
[
[
372,
24,
292
],
[
292,
64,
1070
]
],
[
[
372,
63,
1512
],
[
1512,
25,
1070
]
],
[
[
372,
24,
14
],
[
14,
... | [
[
[
"Clofarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
],
[
"Regoraf... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib and Regorafenib may lead to a major life threatening interaction when taken with Mipomersen
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may le... |
DB00678 | DB09268 | 240 | 1,662 | [
"DDInter1095",
"DDInter1464"
] | Losartan | Picosulfuric acid | Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough simila... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
240,
24,
1662
]
],
[
[
240,
24,
1619
],
[
1619,
63,
1662
]
],
[
[
240,
24,
708
],
[
708,
24,
1662
]
],
[
[
240,
63,
1573
],
[
1573,
... | [
[
[
"Losartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Losartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
... | Losartan may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Losartan may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Co... |
DB08899 | DB11703 | 129 | 405 | [
"DDInter649",
"DDInter9"
] | Enzalutamide | Acalabrutinib | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
129,
25,
405
]
],
[
[
129,
63,
1051
],
[
1051,
24,
405
]
],
[
[
129,
25,
951
],
[
951,
24,
405
]
],
[
[
129,
25,
982
],
[
982,
6... | [
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
],
[
... | Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Enzalutamide may lead to a major life threatening interaction when taken with Palbociclib and... |
DB00860 | DB08880 | 891 | 1,510 | [
"DDInter1513",
"DDInter1771"
] | Prednisolone | Teriflunomide | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
891,
25,
1510
]
],
[
[
891,
62,
1461
],
[
1461,
23,
1510
]
],
[
[
891,
23,
1193
],
[
1193,
62,
1510
]
],
[
[
891,
24,
129
],
[
129,
... | [
[
[
"Prednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Prednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitami... | Prednisolone may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Prednisolone may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zin... |
DB00261 | DB00604 | 702 | 1,425 | [
"DDInter93",
"DDInter385"
] | Anagrelide | Cisapride | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Major | 2 | [
[
[
702,
25,
1425
]
],
[
[
702,
25,
924
],
[
924,
64,
1425
]
],
[
[
702,
6,
7950
],
[
7950,
45,
1425
]
],
[
[
702,
18,
11048
],
[
11048,
... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloperidone"
],
[
"Iloperidone",
"{u} ... | Anagrelide may lead to a major life threatening interaction when taken with Iloperidone and Iloperidone may lead to a major life threatening interaction when taken with Cisapride
Anagrelide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Cisapride (Compound)
Anagrelide (Compound) downregulates VAT1 (Gene) ... |
DB00214 | DB00736 | 1,028 | 660 | [
"DDInter1836",
"DDInter676"
] | Torasemide | Esomeprazole | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Esomeprazole, sold under the brand name Nexium, is a proton pump inhibitor (PPI) medication used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory... | Moderate | 1 | [
[
[
1028,
24,
660
]
],
[
[
1028,
24,
1215
],
[
1215,
40,
660
]
],
[
[
1028,
63,
837
],
[
837,
1,
660
]
],
[
[
1028,
6,
10215
],
[
10215,
... | [
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esomeprazole"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
],
... | Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole (Compound) resembles Esomeprazole (Compound)
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole (Compound) resembles Esomeprazole... |
DB00604 | DB00804 | 1,425 | 1,507 | [
"DDInter385",
"DDInter543"
] | Cisapride | Dicyclomine | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may h... | Moderate | 1 | [
[
[
1425,
24,
1507
]
],
[
[
1425,
25,
359
],
[
359,
62,
1507
]
],
[
[
1425,
25,
1577
],
[
1577,
23,
1507
]
],
[
[
1425,
64,
323
],
[
323,
... | [
[
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
]
],
[
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Chlorothiazide"
],
[
"Chlorot... | Cisapride may lead to a major life threatening interaction when taken with Chlorothiazide and Chlorothiazide may cause a minor interaction that can limit clinical effects when taken with Dicyclomine
Cisapride may lead to a major life threatening interaction when taken with Hydroflumethiazide and Hydroflumethiazide may ... |
DB00757 | DB02959 | 1,166 | 871 | [
"DDInter581",
"DDInter1362"
] | Dolasetron | Oxitriptan | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | 5-Hydroxytryptophan (5-HTP), also known as oxitriptan (INN), is a naturally occurring amino acid and metabolic intermediate in the synthesis of serotonin and melatonin. 5-HTP is sold over-the-counter in the United Kingdom, United States and Canada as a dietary supplement for use as an antidepressant, appetite suppressa... | Major | 2 | [
[
[
1166,
25,
871
]
],
[
[
1166,
63,
475
],
[
475,
24,
871
]
],
[
[
1166,
25,
1053
],
[
1053,
25,
871
]
],
[
[
1166,
64,
121
],
[
121,
... | [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxitriptan"
]
],
[
[
"Dolasetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
... | Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Oxitriptan
Dolasetron may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may lead t... |
DB01042 | DB06643 | 1,307 | 1,136 | [
"DDInter1144",
"DDInter500"
] | Melphalan | Denosumab | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-con... | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Moderate | 1 | [
[
[
1307,
24,
1136
]
],
[
[
1307,
63,
1555
],
[
1555,
24,
1136
]
],
[
[
1307,
24,
1532
],
[
1532,
24,
1136
]
],
[
[
1307,
62,
168
],
[
168... | [
[
[
"Melphalan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Melphalan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
... | Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfam... |
DB08932 | DB11901 | 1,398 | 913 | [
"DDInter1111",
"DDInter107"
] | Macitentan | Apalutamide | Macitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension. It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] due to its lower risk of hepatotoxicity. | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Major | 2 | [
[
[
1398,
25,
913
]
],
[
[
1398,
63,
600
],
[
600,
24,
913
]
],
[
[
1398,
64,
609
],
[
609,
24,
913
]
],
[
[
1398,
24,
1320
],
[
1320,
... | [
[
[
"Macitentan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Macitentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconaz... | Macitentan may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Macitentan may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin... |
DB00361 | DB09052 | 134 | 250 | [
"DDInter1939",
"DDInter220"
] | Vinorelbine | Blinatumomab | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostl... | Moderate | 1 | [
[
[
134,
24,
250
]
],
[
[
134,
24,
949
],
[
949,
63,
250
]
],
[
[
134,
24,
1236
],
[
1236,
24,
250
]
],
[
[
134,
63,
599
],
[
599,
2... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxo... | Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Vinorelbi... |
DB00023 | DB06777 | 305 | 780 | [
"DDInter127",
"DDInter348"
] | Asparaginase Escherichia coli | Chenodeoxycholic acid | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Chenodeoxycholic acid (or Chenodiol) is an epimer of ursodeoxycholic acid (DB01586). Chenodeoxycholic acid is a bile acid naturally found in the body. It works by dissolving the cholesterol that makes gallstones and inhibiting production of cholesterol in the liver and absorption in the intestines, which helps to decre... | Moderate | 1 | [
[
[
305,
24,
780
]
],
[
[
305,
24,
279
],
[
279,
24,
780
]
],
[
[
305,
24,
384
],
[
384,
63,
780
]
],
[
[
305,
25,
1510
],
[
1510,
6... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chenodeoxycholic acid"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when ta... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Anisindione and Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Chenodeoxycholic acid
Asparaginase Escherichia coli may cause a moderate interaction that could exacer... |
DB00581 | DB00703 | 355 | 997 | [
"DDInter1018",
"DDInter1167"
] | Lactulose | Methazolamide | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma. | Moderate | 1 | [
[
[
355,
24,
997
]
],
[
[
355,
24,
471
],
[
471,
1,
997
]
],
[
[
355,
21,
28809
],
[
28809,
60,
997
]
],
[
[
355,
24,
1662
],
[
1662,
... | [
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methazolamide"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetazolamide"
],
... | Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Acetazolamide and Acetazolamide (Compound) resembles Methazolamide (Compound)
Lactulose (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Methazolamide (Compound)
Lactulose may cause a moderate int... |
DB05812 | DB11581 | 1,374 | 1,456 | [
"DDInter8",
"DDInter1926"
] | Abiraterone | Venetoclax | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Major | 2 | [
[
[
1374,
25,
1456
]
],
[
[
1374,
23,
1135
],
[
1135,
23,
1456
]
],
[
[
1374,
24,
1476
],
[
1476,
63,
1456
]
],
[
[
1374,
25,
1375
],
[
13... | [
[
[
"Abiraterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
]
],
[
[
"Abiraterone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",... | Abiraterone may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Venetoclax
Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib... |
DB00515 | DB01208 | 589 | 945 | [
"DDInter387",
"DDInter1705"
] | Cisplatin | Sparfloxacin | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Minor | 0 | [
[
[
589,
23,
945
]
],
[
[
589,
23,
739
],
[
739,
1,
945
]
],
[
[
589,
62,
1176
],
[
1176,
1,
945
]
],
[
[
589,
6,
4973
],
[
4973,
45... | [
[
[
"Cisplatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sparfloxacin"
]
],
[
[
"Cisplatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
],
[
... | Cisplatin may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Sparfloxacin (Compound)
Cisplatin may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Sparfloxacin (Comp... |
DB00401 | DB00902 | 84 | 104 | [
"DDInter1298",
"DDInter1168"
] | Nisoldipine | Methdilazine | Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contractio... | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
84,
24,
104
]
],
[
[
84,
24,
820
],
[
820,
1,
104
]
],
[
[
84,
24,
401
],
[
401,
63,
104
]
],
[
[
84,
1,
1081
],
[
1081,
24,
... | [
[
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Nisoldipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
... | Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Methdilazine (Compound)
Nisoldipine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction ... |
DB09039 | DB15328 | 1,670 | 829 | [
"DDInter629",
"DDInter1896"
] | Eliglustat | Ubrogepant | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor ... | Moderate | 1 | [
[
[
1670,
24,
829
]
],
[
[
1670,
24,
1476
],
[
1476,
24,
829
]
],
[
[
1670,
63,
578
],
[
578,
24,
829
]
],
[
[
1670,
64,
1593
],
[
1593,
... | [
[
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ubrogepant"
]
],
[
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
... | Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagr... |
DB00700 | DB01284 | 312 | 1,042 | [
"DDInter656",
"DDInter1782"
] | Eplerenone | Tetracosactide | Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone c... | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Moderate | 1 | [
[
[
312,
24,
1042
]
],
[
[
312,
1,
1561
],
[
1561,
24,
1042
]
],
[
[
312,
24,
1450
],
[
1450,
63,
1042
]
],
[
[
312,
40,
443
],
[
443,
... | [
[
[
"Eplerenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Eplerenone",
"{u} (Compound) resembles {v} (Compound)",
"Testosterone"
],
[
"Testosterone",
"{u} may cause a... | Eplerenone (Compound) resembles Testosterone (Compound) and Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Eplerenone may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interact... |
DB06605 | DB06779 | 1,409 | 365 | [
"DDInter108",
"DDInter470"
] | Apixaban | Dalteparin | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the r... | Major | 2 | [
[
[
1409,
25,
365
]
],
[
[
1409,
23,
539
],
[
539,
62,
365
]
],
[
[
1409,
63,
305
],
[
305,
24,
365
]
],
[
[
1409,
24,
1496
],
[
1496,
... | [
[
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalteparin"
]
],
[
[
"Apixaban",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",
"... | Apixaban may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Dalteparin
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and... |
DB00400 | DB05239 | 353 | 866 | [
"DDInter843",
"DDInter425"
] | Griseofulvin | Cobimetinib | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Moderate | 1 | [
[
[
353,
24,
866
]
],
[
[
353,
24,
214
],
[
214,
63,
866
]
],
[
[
353,
24,
888
],
[
888,
24,
866
]
],
[
[
353,
63,
1023
],
[
1023,
2... | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
... | Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen an... |
DB00372 | DB06335 | 999 | 761 | [
"DDInter1793",
"DDInter1646"
] | Thiethylperazine | Saxagliptin | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
999,
24,
761
]
],
[
[
999,
24,
1577
],
[
1577,
24,
761
]
],
[
[
999,
24,
1241
],
[
1241,
63,
761
]
],
[
[
999,
25,
684
],
[
684,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethia... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide and Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when tak... |
DB01229 | DB10583 | 973 | 949 | [
"DDInter1377",
"DDInter415"
] | Paclitaxel | Clostridium tetani toxoid antigen (formaldehyde inactivated) | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Clostridium tetani toxoid antigen (formaldehyde inactivated) is a vaccine for intramuscular injection. It is used for active immunization of children 7 years of age or older, and adults, for prevention of tetanus. The toxoid in the Clostridium tetani culture is grown and detoxified followed by purification via ammonium... | Moderate | 1 | [
[
[
973,
24,
949
]
],
[
[
973,
63,
550
],
[
550,
24,
949
]
],
[
[
973,
64,
1377
],
[
1377,
24,
949
]
],
[
[
973,
24,
980
],
[
980,
2... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when t... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab and Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Paclitaxel may lead to a major life threatening interaction ... |
DB00397 | DB06292 | 1,466 | 549 | [
"DDInter1458",
"DDInter474"
] | Phenylpropanolamine | Dapagliflozin | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
1466,
24,
549
]
],
[
[
1466,
24,
1344
],
[
1344,
40,
549
]
],
[
[
1466,
6,
7950
],
[
7950,
45,
549
]
],
[
[
1466,
21,
28898
],
[
28898... | [
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagl... | Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Phenylpropanolamine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Dapagliflozin (Compound)
Phenylpropanolamine (Compound) cause... |
DB00295 | DB01236 | 475 | 679 | [
"DDInter1244",
"DDInter1664"
] | Morphine | Sevoflurane | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 199... | Moderate | 1 | [
[
[
475,
24,
679
]
],
[
[
475,
6,
8374
],
[
8374,
45,
679
]
],
[
[
475,
21,
28862
],
[
28862,
60,
679
]
],
[
[
475,
24,
1133
],
[
1133,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sevoflurane"
]
],
[
[
"Morphine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Morphine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sevoflurane (Compound)
Morphine (Compound) causes Ventricular tachycardia (Side Effect) and Ventricular tachycardia (Side Effect) is caused by Sevoflurane (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00802 | DB01110 | 1,322 | 86 | [
"DDInter43",
"DDInter1209"
] | Alfentanil | Miconazole | A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-ba... | Moderate | 1 | [
[
[
1322,
24,
86
]
],
[
[
1322,
6,
4973
],
[
4973,
45,
86
]
],
[
[
1322,
21,
29122
],
[
29122,
60,
86
]
],
[
[
1322,
25,
222
],
[
222,
... | [
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
]
],
[
[
"Alfentanil",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Alfentanil (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Miconazole (Compound)
Alfentanil (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Miconazole (Compound)
Alfentanil may lead to a major life threatening interaction when taken with Sibutramine an... |
DB00582 | DB08896 | 1,622 | 292 | [
"DDInter1946",
"DDInter1576"
] | Voriconazole | Regorafenib | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Moderate | 1 | [
[
[
1622,
24,
292
]
],
[
[
1622,
63,
79
],
[
79,
1,
292
]
],
[
[
1622,
6,
6017
],
[
6017,
45,
292
]
],
[
[
1622,
54,
19230
],
[
19230,
... | [
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
]
],
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
... | Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib (Compound) resembles Regorafenib (Compound)
Voriconazole (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Regorafenib (Compound)
Voriconazole (Compound) is included by Cytochrome P450 2C9 Inh... |
DB01069 | DB08903 | 401 | 996 | [
"DDInter1533",
"DDInter170"
] | Promethazine | Bedaquiline | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Major | 2 | [
[
[
401,
25,
996
]
],
[
[
401,
24,
649
],
[
649,
1,
996
]
],
[
[
401,
35,
358
],
[
358,
40,
996
]
],
[
[
401,
21,
29282
],
[
29282,
... | [
[
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofe... | Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol (Compound) resembles Bedaquiline (Compound)
Promethazine (Compound) resembles Orphenadrine (Compound) and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Or... |
DB08815 | DB09488 | 154 | 103 | [
"DDInter1104",
"DDInter23"
] | Lurasidone | Acrivastine | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema,... | Moderate | 1 | [
[
[
154,
24,
103
]
],
[
[
154,
63,
85
],
[
85,
24,
103
]
],
[
[
154,
63,
85
],
[
85,
24,
1405
],
[
1405,
24,
103
]
],
[
[
154,
63,
... | [
[
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
],
[
... | Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine ma... |
DB01155 | DB08868 | 872 | 1,011 | [
"DDInter813",
"DDInter737"
] | Gemifloxacin | Fingolimod | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
872,
25,
1011
]
],
[
[
872,
21,
28792
],
[
28792,
60,
1011
]
],
[
[
872,
62,
112
],
[
112,
23,
1011
]
],
[
[
872,
24,
144
],
[
144,
... | [
[
[
"Gemifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Gemifloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal disorder"
],
[
"Gastrointestinal disorder",
"{u} ... | Gemifloxacin (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Fingolimod (Compound)
Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit cl... |
DB01233 | DB06204 | 1,311 | 768 | [
"DDInter1197",
"DDInter1746"
] | Metoclopramide | Tapentadol | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA... | Moderate | 1 | [
[
[
1311,
24,
768
]
],
[
[
1311,
6,
17589
],
[
17589,
45,
768
]
],
[
[
1311,
21,
29081
],
[
29081,
60,
768
]
],
[
[
1311,
63,
1123
],
[
11... | [
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tapentadol"
]
],
[
[
"Metoclopramide",
"{u} (Compound) binds {v} (Gene)",
"HTR3A"
],
[
"HTR3A",
"{u} (Gene) is bound by {v} (Compo... | Metoclopramide (Compound) binds HTR3A (Gene) and HTR3A (Gene) is bound by Tapentadol (Compound)
Metoclopramide (Compound) causes Angioedema (Side Effect) and Angioedema (Side Effect) is caused by Tapentadol (Compound)
Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Propant... |
DB04574 | DB12500 | 177 | 283 | [
"DDInter684",
"DDInter714"
] | Estrone sulfate (topical) | Fedratinib | Estrone 3-sulfate is a steroid sulfate that is the 3-sulfate of estrone. It has a role as a human metabolite and a mouse metabolite. It is a 17-oxo steroid and a steroid sulfate. It is functionally related to an estrone. It is a conjugate acid of an estrone 3-sulfate(1-). It derives from a hydride of an estrane. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
177,
24,
283
]
],
[
[
177,
63,
1419
],
[
1419,
24,
283
]
],
[
[
177,
24,
98
],
[
98,
24,
283
]
],
[
[
177,
40,
559
],
[
559,
24,... | [
[
[
"Estrone sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Estrone sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
... | Estrone sulfate may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Estrone sulfate may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Estr... |
DB00284 | DB06016 | 1,647 | 1,508 | [
"DDInter11",
"DDInter300"
] | Acarbose | Cariprazine | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are r... | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in... | Moderate | 1 | [
[
[
1647,
24,
1508
]
],
[
[
1647,
24,
1021
],
[
1021,
24,
1508
]
],
[
[
1647,
24,
98
],
[
98,
63,
1508
]
],
[
[
1647,
23,
135
],
[
135,
... | [
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
],
[
... | Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide and Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem ... |
DB01309 | DB14751 | 1,254 | 388 | [
"DDInter933",
"DDInter1132"
] | Insulin glulisine | Mecasermin rinfabate | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Mecasermin rinfabate is approved for severe primary insulin-like growth factor (IGF) deficiency or in patients with GH gene deletion who have developed antibodies to growth hormone (GH). Mecasermin rinfabate is similar to in that both drugs contain recombinant DNA origin insulin-like growth factor 1 (IGF-1). Mecasermin... | Moderate | 1 | [
[
[
1254,
24,
388
]
],
[
[
1254,
24,
877
],
[
877,
24,
388
]
],
[
[
1254,
63,
959
],
[
959,
24,
388
]
],
[
[
1254,
24,
877
],
[
877,
... | [
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mecasermin rinfabate"
]
],
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mac... | Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Mecasermin rinfabate
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00586 | DB00631 | 1,512 | 372 | [
"DDInter537",
"DDInter405"
] | Diclofenac | Clofarabine | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Moderate | 1 | [
[
[
1512,
24,
372
]
],
[
[
1512,
6,
7720
],
[
7720,
46,
372
]
],
[
[
1512,
21,
28903
],
[
28903,
60,
372
]
],
[
[
1512,
63,
1467
],
[
1467... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Diclofenac",
"{u} (Compound) binds {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is upregulated by {v} (Compou... | Diclofenac (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Clofarabine (Compound)
Diclofenac (Compound) causes Dry skin (Side Effect) and Dry skin (Side Effect) is caused by Clofarabine (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Enoxacin and En... |
DB00777 | DB09038 | 146 | 1,450 | [
"DDInter1537",
"DDInter636"
] | Propiomazine | Empagliflozin | Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Struct... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
146,
24,
1450
]
],
[
[
146,
63,
1179
],
[
1179,
24,
1450
]
],
[
[
146,
1,
104
],
[
104,
24,
1450
]
],
[
[
146,
40,
9
],
[
9,
24,... | [
[
[
"Propiomazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Propiomazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
... | Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Propiomazine (Compound) resembles Methdilazine (Compound) and Methdilazine may cause a moderate int... |
DB00662 | DB01563 | 717 | 680 | [
"DDInter1873",
"DDInter349"
] | Trimethobenzamide | Chloral hydrate | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | A hypnotic and sedative used in the treatment of insomnia. The safety margin is too narrow for chloral hydrate to be used as a general anesthetic in humans, but it is commonly used for that purpose in animal experiments. It is no longer considered useful as an anti-anxiety medication. | Moderate | 1 | [
[
[
717,
24,
680
]
],
[
[
717,
24,
272
],
[
272,
24,
680
]
],
[
[
717,
63,
1614
],
[
1614,
24,
680
]
],
[
[
717,
24,
1609
],
[
1609,
... | [
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloral hydrate"
]
],
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorphe... | Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Chloral hydrate
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when t... |
DB00342 | DB09054 | 1,181 | 384 | [
"DDInter1770",
"DDInter905"
] | Terfenadine | Idelalisib | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
1181,
24,
384
]
],
[
[
1181,
25,
318
],
[
318,
23,
384
]
],
[
[
1181,
64,
1230
],
[
1230,
23,
384
]
],
[
[
1181,
24,
555
],
[
555,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Escitalopram"
],
[
"Escita... | Terfenadine may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Terfenadine may lead to a major life threatening interaction when taken with Citalopram and Citalopram may cause a minor int... |
DB01005 | DB10316 | 995 | 334 | [
"DDInter894",
"DDInter1248"
] | Hydroxyurea | Mumps virus strain B level jeryl lynn live antigen | Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, h... | Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease. | Major | 2 | [
[
[
995,
25,
334
]
],
[
[
995,
64,
1057
],
[
1057,
25,
334
]
],
[
[
995,
24,
328
],
[
328,
25,
334
]
],
[
[
995,
25,
908
],
[
908,
2... | [
[
[
"Hydroxyurea",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Hydroxyurea",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
... | Hydroxyurea may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Mercaptop... |
DB01083 | DB01276 | 1,142 | 123 | [
"DDInter1348",
"DDInter706"
] | Orlistat | Exenatide | The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical inter... | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
1142,
24,
123
]
],
[
[
1142,
63,
1560
],
[
1560,
24,
123
]
],
[
[
1142,
24,
34
],
[
34,
63,
123
]
],
[
[
1142,
24,
279
],
[
279,
... | [
[
[
"Orlistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Orlistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
... | Orlistat may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Orlistat may cause a moderate interaction that could exacerbate diseases when taken with Fosamprenavir and Fosa... |
DB00549 | DB09083 | 522 | 880 | [
"DDInter1955",
"DDInter996"
] | Zafirlukast | Ivabradine | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus r... | Moderate | 1 | [
[
[
522,
24,
880
]
],
[
[
522,
24,
1478
],
[
1478,
24,
880
]
],
[
[
522,
24,
159
],
[
159,
63,
880
]
],
[
[
522,
63,
597
],
[
597,
2... | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivabradine"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
... | Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Lar... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.